Puma Biotechnology Inc. (Nasdaq: PBYI) reported positive results from a Phase II clinical trial of PB272 to treat HER2-positive metastatic breast cancer sending the stock price up $1.70 to close at $83.65.
Puma Biotechnology reports positive trial results
June 05, 2017 at 18:46 PM EDT
